Even Medical Marijuana Research is Set to Benefit from Banking Reform
Lawmakers are once again trying to give the green light to cannabis banking legislation in states where it’s legal. With classic banking services potentially becoming available for marijuana dispensaries, how will this impact the sale of medical-grade cannabis products? Michael Sassano, the Chairman and CEO at Somai Pharmaceuticals weighs in. With these potential developments, it begs…
This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.
Get featured
Want to get featured in MarketScale Healthcare?
Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.
Lawmakers are once again trying to give the green light to cannabis banking legislation in states where it’s legal. With classic banking services potentially becoming available for marijuana dispensaries, how will this impact the sale of medical-grade cannabis products? Michael Sassano, the Chairman and CEO at Somai Pharmaceuticals weighs in.
With these potential developments, it begs the question: does this banking reform open the door for a more frictionless research pipeline? Michael shares some interesting statistics on where things stand researching cannibanoids for pharmaceuticals and medical applications.
Your experts belong here
Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.
Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.